Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Xilio Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
6.34
43.8
Research and development
43.9
51.2
59.2
52.1
41.2
56
General and administrative
10.7
23.9
29.9
27
24.8
29.7
Operating expenses
54.6
75
89.1
79.1
66.9
85.7
Operating income
-54.6
-75
-89.1
-79.1
-60.6
-42
Other non-operating income
-0.66
-0.76
0.93
2.73
2.34
6.95
Pre-tax income
-58.2
-35
Income tax
0
0
0
0
0
0
Net income
-55.2
-75.8
-88.2
-76.4
-58.2
-35
EBITDA
-53.5
-73.5
-87.3
-77.2
-58.9
-40.4
EPS, basic
-1,474.00
-189.03
-45.02
-38.87
-15.24
-4.19
EPS, diluted
-1,474.00
-189.03
-45.02
-38.87
-15.24
-4.19
Shares, basic (weighted)
0.04
0.4
1.96
1.97
3.82
8.36
Shares, diluted (weighted)
0.04
0.4
1.96
1.97
3.82
8.36
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
19.2
198
120
44.7
55.3
138
Other current assets
0.04
4.46
4.11
3.42
4.94
2.5
Total current assets
20.6
203
124
48.1
60.2
145
Property, plant and equipment
7.37
7.62
7.26
5.94
4.47
3.89
Lease right-of-use assets
6.31
5.98
5.59
5.13
4.59
3.96
Other non-current assets
0.5
0.39
0.27
0.15
Total assets
36.3
218
139
60.9
71.1
155
Accounts payable
5.44
3.14
3.13
1.05
2.57
3.17
Accrued liabilities
13.7
8.75
10.3
10.5
9.98
11.7
Deferred revenue
13.5
40
Total current liabilities
22.2
12.8
21.1
16
27.3
56.3
Long-term debt
7.41
9.63
3.17
Lease liabilities
10.9
10.1
9.19
8.14
6.95
5.61
Other non-current liabilities
1.13
0.12
0.05
Total liabilities
41.6
32.6
33.5
24.1
53.5
119
Paid-in capital
1.8
346
355
362
401
454
Retained earnings
-85.1
-161
-249
-326
-384
-419
Shareholders' equity
-83.3
185
106
36.8
17.6
35.3
Total equity
-83.3
185
106
36.8
17.6
35.3
Total liabilities and equity
36.3
218
139
60.9
71.1
155
Shares outstanding
0.05
1.96
1.96
1.97
3.27
4.53
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-55.2
-75.8
-88.2
-76.4
-58.2
-35
Depreciation and amortization
1.07
1.5
1.85
1.9
1.64
1.54
Stock-based compensation
1.3
4.96
8.42
7.38
6.43
6.94
Change in receivables
-5
Change in payables
2.93
-2.82
0.49
-2.06
1.53
0.15
Cash from operations
-36.1
-80.8
-75.7
-68.6
-18.4
-4.99
Capital expenditures
-2.19
-1.1
-1.87
-0.49
-0.04
-0.52
Cash from investing
-2.19
-1.1
-1.87
-0.49
-0.04
-0.52
Debt issued
0.98
Debt repaid
-1
-6.67
-3.33
Stock issued
0.16
116
0.02
0.01
0.01
0.01
Cash from financing
10
261
-0.07
-6.55
29.2
87.8
Net change in cash
-28.3
179
-77.7
-75.7
10.8
82.3
Free cash flow
-38.3
-81.9
-77.6
-69.1
-18.4
-5.51
Interest paid
0.54
0.49
0.56
0.57
0.06
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.04 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-48.9%
Operating income / revenue.
EBITDA margin
-47.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-34.1%
Net income / revenue.
FCF margin
-95.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-94.5%
Cash from operations / revenue.
Return on equity (ROE)
-30.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-14.2%
Net income / average total assets.
R&D / revenue
104.3%
Research and development expense / revenue.
Stock-based pay / revenue
12.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.0%
Capital expenditures / revenue.
D&A / revenue
2.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
589.9%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
100.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-30.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
117.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
3.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
33.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
118.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
62.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
194.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.25x
Current assets / current liabilities.
Quick ratio
3.98x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.98x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.30
Revenue / diluted weighted shares.
FCF per share
-$3.16
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.12
Cash from operations / diluted weighted shares.
Book value per share
$10.98
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.93x
Market cap / revenue.
P/B
0.82x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.82x
Market cap / tangible book value, when positive.
FCF yield
-103.0%
Free cash flow / market cap.
Earnings yield
-36.7%
Net income / market cap (the inverse of P/E).
What was Xilio Therapeutics, Inc.'s revenue in fiscal 2025?
Xilio Therapeutics, Inc. reported revenue of $43.8M for fiscal 2025, 589.9% higher than the year before.
Was Xilio Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $35.0M.
How much free cash flow did Xilio Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $5.0M minus capital expenditures of $518.0K left free cash flow of -$5.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.